AstraZeneca (NASDAQ: AZN) has arguably been one of the more disappointing coronavirus vaccine stocks. Over the past year, its shares have returned a total of 2.1% to investors, which is far less than the S&P 500's 15% gain during the same period. In the eyes of many onlookers, the $134 billion market cap biotech has reached the peak of its growth cycle, and its prospects for 2021 and beyond seem bleak.
Just what could be so controversial about this pharmaceutical giant's growth catalysts? Should investors give its stock a chance or look for better alternatives?
Image Source: Getty Images.
Source Fool.com